R ates of death from coronary heart disease in the United States underwent profound secular changes during the 20th century. 1,2 After peaking around 1968, age-adjusted rates were cut in half. Two factors may have contributed to this decline.
First, there have been substantial decreases in the prevalence of some major cardiovascular risk factors, including smoking, elevated total cholesterol, and high blood pressure. [3] [4] [5] [6] [7] [8] However, the prevalence of both obesity and diabetes has increased alarmingly. [9] [10] [11] Second, there has been a revolution in the treatments for established coronary heart disease, with major breakthroughs in evidence-based therapies, including the use of thrombolysis, coronary-artery bypass grafting (CABG), coronary angioplasty and stents, and angiotensin-converting-enzyme (ACE) inhibitors and statins.
The annual direct and indirect costs for coronary heart disease were $142.5 billion in 2006, and they continue to rise. 12 Determining the respective contributions of prevention and therapy to the declines in mortality from coronary heart disease is therefore becoming increasingly important, for the purposes of both understanding past trends and planning future strategies. Estimates of the contribution from reductions in risk factors before 1990 have ranged from 50 to 54% in the United States 13,14 and from 44 to 76% in other industrialized countries. [15] [16] [17] [18] [19] [20] [21] [22] However, to our knowledge, no U.S. studies have considered the dramatic changes since 1990 or have attempted to quantify the relative contributions of specific therapies and trends in risk factors. We therefore applied a model that has been used successfully in several other countries to examine trends in U.S. deaths from coronary heart disease between 1980 and 2000.
Me thods

Mortality Model and Data Sources
To examine the contributions of various factors to the changes in rates of death from coronary heart disease among U.S. adults 25 to 84 years of age, we used an updated version of the IMPACT mortality model, which was previously validated in Europe, New Zealand, This model has been described in detail elsewhere. 18, 19, 23, 24 It incorporates major population risk factors for coronary heart disease (smoking, high blood pressure, elevated total cholesterol, obesity, diabetes, and physical inactivity) and all usual medical and surgical treatments for coronary heart disease.
Wherever possible, data sources specific to the U.S. population were used to construct the U.S. model. When more than one data source was available, we chose the source that we considered to be most representative, least biased, and most up-to-date. Detailed information on the IMPACT model and data sources for the U.S. analysis is provided in the Supplementary Appendix, available with the full text of this article at www. nejm.org.
Deaths Prevented or Postponed
Data on the total U.S. population and age distribution in 1980 and 2000 were obtained from the U.S. Census Bureau. Deaths according to age and sex and mortality rates associated with coronary heart disease in 1980 and 2000 were obtained from the National Vital Statistics System of the National Center for Health Statistics. We calculated the number of deaths from coronary heart disease that would have been expected in 2000 if the mortality rates in 1980 had remained unchanged by multiplying the age-specific mortality rates for 1980 by the population for each 10-year age stratum in the year 2000 (thus accounting for the aging of the population). Subtracting the number of deaths observed in 2000 from the number expected then yielded the drop in the number of deaths (prevented or postponed) in 2000 that the model would have to explain.
Treatments and Mortality Reductions
The prevalence of coronary heart disease by diagnosis, the estimated frequency of use of specific treatments, the case fatality rate by diagnosis, and the risk reduction due to treatment, all stratified by age and sex, were obtained from published sources (Tables 2 through 5 in the Supplementary Appendix). The number of deaths prevented or postponed as a result of each intervention in each group of patients in the year 2000 (Table 1) was calculated by multiplying the number of people in each diagnostic group by the proportion of those patients who received a particular treatment, by the case fatality rate over a period of 1 year, and by the relative reduction in the 1-year case fatality rate that was accounted for by the treatment. 19, 20 ages of 55 and 64 years were hospitalized with acute myocardial infarction. Some 84% were given aspirin, with an expected mortality reduction of 15%. 25 The expected age-specific, 1-year case fatality rate was approximately 5.4%. 26 The number of deaths prevented or postponed for at least a year by the use of aspirin among men in this age group was then calculated as 102,280 × 0.84 × 0.15 × 0.054 = 696. Several adjustments were made to these basic analyses. Although most of the therapeutic measures studied were not in use in 1980, in some cases such use was already substantial (e.g., CABG for stable angina pectoris). In such cases, the number of deaths prevented or postponed as a result of the therapy as used in 1980 was calculated and subtracted from the number of deaths for 2000 to calculate the net benefit. We assumed that compliance -the proportion of treated patients actually taking therapeutically effective levels of medication -was 100% among hospitalized patients, 70% among symptomatic patients in the community, and 50% among asymptomatic patients in the community. 19, 24, 27, 28 To avoid double counting of patients treated, we identified potential overlaps between different groups of patients and made appropriate adjustments ( Table 9 in the Supplementary Appendix). For example, heart failure develops within 1 year after acute myocardial infarction in approximately one quarter of survivors, and approximately half the patients undergoing CABG have had a previous myocardial infarction. 19, 24 To address the potential effect on the relative reduction in the case fatality rate for individual patients receiving multiple treatments, we used the Mant and Hicks cumulative-relative-benefit approach 29 :
relative benefit = 1 − (1 − relative reduction in case fatality rate for treatment A) × (1 − relative reduction in case fatality rate for treatment B) × . . . × (1 − relative reduction in case fatality rate for treatment N).
Risk Factors and Mortality Reductions
Two approaches were used to calculate the numbers of deaths prevented or postponed as a result of changes in risk factors. We used a regression approach for systolic blood pressure, cholesterol, and body-mass index. The number of deaths prevented or postponed as a result of the change in the prevalence of or mean value for each of these risk factors (Table 2 ) was estimated as the product of three variables: the number of deaths from coronary heart disease in 1980 (the base year), the subsequent reduction in that risk factor (Table 2 in the Supplementary Appendix), and the regression coefficient quantifying the change in mortality from coronary heart disease per unit of absolute change in the risk factor (Table 6 in the Supplementary Appendix). For example, in 1980, there were 26,352 deaths from coronary heart disease among 12,629,000 women who were 55 to 64 years of age. The mean systolic blood pressure in this group decreased by 3.09 mm Hg between 1980 and 2000. The largest meta-analysis showed an estimated age-and sex-specific reduction in mortality of 50% for every reduction of 20 mm Hg in systolic pressure, yielding a logarithmic (ln) coefficient of -0.035. 33 The number of deaths prevented or postponed as a result of this change was then estimated as follows: The population-attributable risk fraction was used to determine the effect of changes in the prevalence of smoking, diabetes, and physical inactivity. The population-attributable risk fraction was calculated conventionally as [P × (RR−1)] ÷ [(1+P) × (RR−1)], where P is the prevalence of the risk factor ( Table 2 in the Supplementary Appendix) and RR is the relative risk of death from coronary heart disease associated with that risk factor (Table 7 in the Supplementary Appendix). The number of deaths prevented or postponed was then estimated as the number of deaths from coronary heart disease in 1980 (the base year) multiplied by the difference between the population-attributable risk fraction in 1980 and that in 2000 (Table 2 ). For example, the prevalence of diabetes among men 65 to 74 years of age increased from 14.5% in 1980 to 20.7% in 2000. Given a relative risk of 1.93, the population-attributable risk fraction increased from 0.119 to 0.161. Additional deaths from coronary heart disease in 2000 that were attributable to an increased prevalence of diabetes were therefore calculated as follows 18, 19, 23, 24 : that there was no further synergy between the treatment and risk-factor sections of the model or among the major risk factors. The number of deaths prevented or postponed as a result of changes in risk factors was systematically quantified for each specific patient group to account for potential differences in effect. Lag times between the change in the riskfactor rate and the change in the event rate were not modeled; it was assumed that these lag times would be relatively unimportant over a period of two decades. 20, 23, 34, 35 
Comparison of Estimated and Observed Mortality Changes
The model estimates for the total number of deaths prevented or postponed by each treatment and for each risk-factor change were rounded to the nearest multiple of 5 (e.g., 696 became 695). All these figures were then summed and compared with the observed changes in mortality for men and women in each age group. Any shortfall in the overall model estimate was then presumed to be attributable either to inaccuracies in our calculated estimates or to other, unmeasured risk factors. 19, 20, 24 
Sensitivity Analyses
We tested all the above assumptions and variables in a multiple-way sensitivity analysis, using the analysis-of-extremes method. 19, 20, 24, 36 For each variable in the model, we assigned a lower value and an upper value, using 95% confidence intervals when available and otherwise using ±20% (for the number of patients, use of treatment, and compliance). For example, for aspirin treatment in men 55 to 64 years of age who were hospitalized with acute myocardial infarction, the best estimate was 696 deaths prevented or postponed. The minimum estimate from the multipleway sensitivity analysis was 259, and the maximum estimate was 1501 (Table 3) .
R e sult s
From 1980 to 2000, the age-adjusted rate of coronary heart disease fell from 542.9 to 266.8 cases per 100,000 population among men aged 25 to 84 years and from 263.3 to 134.4 among women aged 25 to 84 years. In 1980, a total of 462,984 deaths among people in this age group were recorded as due to coronary heart disease, according to the International Classification of Diseases, . 41 In 2000, a total of 337,658 such deaths were recorded, according to the International Classification of Diseases, 10th Revision (codes I20-I25). 42 However, had the agespecific death rates from 1980 remained in 2000, an additional 341,745 deaths from coronary heart disease would have occurred.
The U.S. IMPACT model explained approximately 308,965 (90%) of this decrease in the number of deaths from coronary heart disease. Under the assumptions of the sensitivity analysis, the minimum and maximum numbers of deaths from coronary heart disease that were explained were 175,230 (51%) and 545,755 (160%). The agreement between the number of estimated deaths and the number of observed deaths was reasonably good for men across all groups and for women under the age of 75 years (Fig. 1) . Changes in medical treatments accounted for approximately 47% and risk-factor changes accounted for approximately 44% of the decrease in deaths (Tables 1 and 2 ).
Medical and Surgical Treatments
Approximately 159,330 of the deaths from coronary heart disease that were prevented or postponed were attributable to medical therapies (minimum estimate, 58,065; maximum estimate, 347,395) ( Table 1 ). The largest reductions in deaths came from the use of secondary-prevention medications or rehabilitation after acute myocardial infarction or after revascularization (a total reduction of approximately 35,800 deaths) and from the use of initial treatments for acute myocardial infarction or unstable angina (approximately 35,145 deaths), followed by treatments for heart failure and hypertension, statin therapy for primary prevention, and treatments for chronic angina. The use of revascularization for chronic angina resulted in a reduction of approximately 15,690 deaths in 2000, as compared with deaths in 1980, or approximately 5% of the total.
Risk Factors
Approximately 149,635 fewer deaths from coronary heart disease were attributable to changes in risk factors (minimum estimate, 117,165; maximum estimate, 198,360) (Table 2) . Decreases in the total cholesterol concentration (by 0.34 mmol per liter), systolic blood pressure (by 5.1 mm Hg), and smoking prevalence (by 11.7%) were estimated to have prevented or postponed approximately 82,830, 68,800, and 39,925 deaths, respectively. The 2.3% decrease in physical inactivity prevented or postponed approximately 17,445 deaths. In contrast, the increase in the body-mass index (the weight in kilograms divided by the square of the height in meters) of 2.6 and the 2.9% increase in the prevalence of diabetes resulted in approximately 25,905 and 33,465 additional deaths overall, respectively (Table 2) .
Proportional Contributions to the Decrease in Deaths
Sensitivity analyses showed that the proportional contributions of specific treatments and risk-factor changes to the overall reduction in deaths from coronary heart disease in 2000 were relatively consistent (Tables 1 and 2 ). Thus, all initial treatments for acute myocardial infarction together accounted for approximately 21,570 fewer deaths, representing 6.3% of the total decrease of 341,745 deaths. The minimum estimated contribution was 9045 fewer deaths (2.6%), and the maximum was 37,720 (11.0%). The contribution of treatments for acute myocardial infarction therefore remained consistently smaller than that of secondary prevention or therapies for heart failure, irrespective of whether best, minimum, or maximum estimates were compared (Table 1) .
Dis cus sion
The burden of coronary heart disease in the United States remains enormous, even though associated mortality rates fell by more than 40% between 1980 and 2000. These two decades saw rapid growth in costly medical technology and pharmaceutical treatments for coronary heart disease, as well as substantial public health efforts to reduce The bars show the observed decrease in deaths in each age group, and the vertical lines the extreme minimum and maximum estimates in the sensitivity analysis. the prevalence of major cardiovascular risk factors. Establishing the relative contributions of these two approaches is therefore of considerable importance. We found that reductions in major risk factors probably accounted for approximately half the decrease in deaths from coronary heart disease, as in most other industrialized countries studied. 15-22 Earlier U.S. studies likewise suggested a contribution of approximately 54% of the reduction in deaths between 1968 and 1976 14 and approximately 50% between 1980 and 1990. 13 Irrespective of the assumptions used, we found that the largest contributions from medical therapies consistently came from secondary prevention, followed by treatments for acute coronary syndromes, then heart failure. Revascularization by means of CABG or angioplasty for stable or unstable disease together accounted for approximately 7% of the overall drop in deaths from coronary heart disease, a finding that is consistent with the results of previous studies in the United States 43 and elsewhere. [19] [20] [21] [22] 44 Although most of the changes in treatments and risk factors between 1980 and 2000 led to reductions in deaths from coronary heart disease, two major exceptions are noteworthy. Our analysis estimated that increases in the body-mass index accounted overall for about 26,000 additional deaths from coronary heart disease in 2000 and increases in the prevalence of diabetes for about 33,500 additional deaths; both figures are consistent with the results of other recent studies. 45, 46 Efforts to address these two risk factors should therefore receive particular attention in future measures to improve the public health. 10, 11 Modeling studies have a number of potential strengths, including the ability to transparently integrate and simultaneously consider huge amounts of data from many sources and then test explicit assumptions by means of sensitivity analyses. Our analysis of extremes suggested that the proportional contributions to the overall reductions in deaths from specific treatments and riskfactor changes remained reasonably consistent, irrespective of whether best, minimum, or maximum estimates were considered (Tables 1 and 2) . This was reassuring, as was the general consistency with the results of most studies performed elsewhere (Fig. 2) . [15] [16] [17] 19, 20 However, all modeling analyses should be interpreted with appropriate caution. All require the gathering of data from numerous sources, each with recognized limitations. We sometimes had to use data from studies that might have been limited by geographic, ethnic, or selection bias or by the need to extrapolate to older age groups. Risk estimates were not necessarily fully independent of each other. Furthermore, most interactions were averaged across broad groups. We therefore made the explicit assumptions detailed in the Supplementary Appendix. Furthermore, we analyzed only the estimated reduction in deaths from coronary heart disease, not life-years gained or improvement in the quality of life. 47 Analyses of these changes are warranted, as well as comparisons among racial and ethnic groups and economic analyses.
The estimates of changes in risk factors remain imprecise. Furthermore, we did not explicitly consider the effect of lag times; however, they may be relatively unimportant over a 20-year period. 20, 23, 33, 35 Although major efforts were made to address overlaps, residual double counting of some individual patients remains possible. We In the New Zealand study, 1974 to 1981 (Beaglehole 15 ), the analysis focused on specific treatments and inferred contribution from risk factors. In the Finland study, 1972 to 1992 (Vartiainen et al. 16 ), the analysis focused on risk factors and inferred contribution from treatments.
Copyright © 2007 Massachusetts Medical Society. All rights reserved. also assumed that, after adjustments for reduced dosing and imperfect compliance, the efficacy of treatments in randomized, controlled trials could be generalized to usual clinical practice. 48, 49 Both assumptions may have potentially overestimated the true treatment effect.
In conclusion, our analyses suggest that approximately half the recent decrease in deaths from coronary heart disease in the United States may be attributable to reductions in major risk factors and approximately half to evidence-based medical therapies. Future strategies for preventing and treating coronary heart disease should therefore be comprehensive, maximizing the coverage of effective treatments and actively promoting population-based prevention by reducing risk factors.
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